3 completed, 3 terminated, 1 active not recruiting. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 3, Terminated 3, Active not recruiting 1 |
Follow Macitentan 10 mg: new trials by email Literature Review of Macitentan 10 mg trials Research Report on Macitentan 10 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg - Pulmonary Arterial Hypertension | Phase 3 | Active not recruiting | Actelion | 935 | 2020-06-30 | 2026-11-03 |
| Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg - Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Phase 3 | Completed | Actelion | 187 | 2019-07-29 | 2025-12-19 |
| An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients. macitentan 10 mg - Congenital Heart Disease With Fontan Circulation | Phase 3 | Terminated | Actelion | 112 | 2019-04-11 | 2023-03-07 |
| A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH). macitentan 10 mg - Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | Phase 3 | Terminated | Actelion | 9 | 2019-01-08 | 2021-06-18 |
| Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects Macitentan 10 mg, Placebo - Congenital Heart Disease | Phase 3 | Completed | Actelion | 142 | 2017-08-14 | 2025-03-30 |
| Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome Macitentan 10 mg, Placebo - Pulmonary Arterial Hypertension | Phase 3 | Completed | Actelion | 226 | 2013-05-21 | 2018-02-23 |
| Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients Macitentan 3 mg, Macitentan 10 mg, Placebo - Digital Ulcers | Phase 3 | Terminated | Actelion | 265 | 2011-12-01 | 2025-02-04 |
Pulmonary Arterial Hypertension (3) · Eisenmenger Complex (1) · Heart Defects, Congenital (1) · Scleroderma, Systemic (1) · Univentricular Heart (1) · digital ulcers (1)
Actelion (7)
China (5) · Poland (5) · United States (5) · Australia (4) · Canada (4) · Czechia (4) · France (4) · Germany (4) · Taiwan (4) · United Kingdom (4) · Bulgaria (3) · Denmark (3) · Japan (3) · Malaysia (3) · Mexico (3)
Hany Rofael, MD (1) · Thierry Francis Briand, MD (1) · Yoshinari Yokoyama, PhD (1)
PMID 27163986, PMID 30586694, PMID 38267108, PMID 41250682, PMID 41820779, PMID 42023995
2014 (1), 2016 (1), 2018 (1), 2019 (1)